Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in cell and gene therapy, today provided a business and strategy update and reported 2021 financial results."We...
Investing.com – U.S. equities were lower at the close on Friday, as losses in the Oil & Gas, Financials and Industrials sectors propelled shares lower. At the close in NYSE, the...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highsBoth Iran, US likely looking...
early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VIITAL™ reveal significant scope for pain reduction and EB-101...
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) and ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM Capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs. It is applying AIM Capsid Technology to develop in-vivo gene therapies.